Company Overview

BRIDGEBIO ONCOLOGY THERAPEUTICS, INC.

BBOT
Annual
Revenue vs. Cost of Revenue
Revenue Cost of Revenue
Total Operating Expenses vs. Operating Income
Total Operating Expenses Operating Income
Net Income
Net Income
Revenue
—M
2025 FY
Net Income
-134M
2025 FY
Shares Outstanding
31M
2025 FY
EPS
-4.3USD
2025 FY
Company Information
SIC Code
2834
CIK Code
1869105
Exchange
Nasdaq
Location
US